Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Chile | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: INFAI
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Essential Tremor
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 1R03DC012429-01A1 | P2 |
Completed |
Essential Tremor |
2016-12-22 |
|
| 13COBT | P2 |
Active, not recruiting |
Unknown |
2013-01-06 |
|
| 12-N-0024 | P1 |
Completed |
Essential Tremor |
2012-07-18 |
|
| 09-N-0084 | P2 |
Completed |
Essential Tremor |
2010-11-01 |